Human CD19 Monoclonal Antibody

Catalog No.: YR0501



Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/ μ g)Determined by LAL gel clotting assay

Sterility

 $0.2\ \mu m$ filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone

Loncastuximab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

RecommendedIsotype Control(s)

Recommended Dilution Buffer

1×PBS pH 7.3

Contact

6	400-999-6126
\bowtie	cn.market@abclonal.com.cn
•	www.abclonal.com.cn

Product Information

Production


Purification


Purified from cell culture supernatant in an animal-free facility

Protein A or G purification

Storage

Store at $2 - 8^{\circ}$ C. $2 - 8^{\circ}$ C for up to 4 weeks and -80° C for long term storage (Avoid repeated freezing and thawing)





Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD19 (Research Grade Loncastuximab Biosimilar) Monoclonal Antibody to CD19. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Human CD19 SPR assay. Determined through SPR assay, the Human Anti-Human CD19 (Research Grade Loncastuximab Biosimilar) Monoclonal Antibody is Capable of binding to Human CD19 with an affinity constant of 1.193n M.